Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Short term Debt (2018 - 2020)

Summit Therapeutics filings provide 3 years of Short term Debt readings, the most recent being -$102549.2 for Q1 2020.

  • Quarterly Short term Debt changed N/A to -$102549.2 in Q1 2020 from the year-ago period, while the trailing twelve-month figure was -$102549.2 through Mar 2020, changed N/A year-over-year, with the annual reading at $105000.0 for FY2019, N/A changed from the prior year.
  • Short term Debt hit -$102549.2 in Q1 2020 for Summit Therapeutics, roughly flat from -$102858.0 in the prior quarter.
  • Across five years, Short term Debt topped out at -$98000.0 in Q3 2019 and bottomed at -$1.1 million in Q4 2018.
  • Average Short term Debt over 3 years is -$449215.7, with a median of -$102858.0 recorded in 2019.
  • Peak annual rise in Short term Debt hit 91.13% in 2019, while the deepest fall reached 91.13% in 2019.
  • Summit Therapeutics' Short term Debt stood at -$1.1 million in 2018, then surged by 90.79% to -$102858.0 in 2019, then grew by 0.3% to -$102549.2 in 2020.
  • Per Business Quant, the three most recent readings for SMMT's Short term Debt are -$102549.2 (Q1 2020), -$102858.0 (Q4 2019), and -$99015.2 (Q4 2019).